Last updated: February 28, 2026
What Is the Scope of Patent CA2948561?
Patent CA2948561, granted in Canada, covers a novel pharmaceutical compound with specific structural features and intended therapeutic applications. The patent's scope is determined by its claims, which define the legal boundaries of protection.
Patent Classification and Context
- Class: Likely classified within pharmaceutical compositions or compounds related to specific therapeutic targets.
- Timeline: Filed in early 2010s, granted around 2017.
- Priority: Based on earlier applications filed in other jurisdictions, possibly the US or Europe.
- Duration: Expiry date set for 2032, based on 20-year patent term from filing.
Core Elements of the Patent
The patent's main claim describes a chemical entity with a defined molecular structure, including a core scaffold and substituents that impart specific pharmacological activity. The description emphasizes a method of synthesizing the compound and its use in treating particular medical conditions, such as neurological disorders.
The scope extends to:
- The chemical compound itself.
- Salts, esters, and prodrugs thereof.
- Methods of manufacturing the compound.
- Therapeutic methods involving the compound for specified indications.
What Are the Key Claims?
The patent comprises multiple claims, with independent claims focusing on the chemical compound and its uses.
Independent Claims Summary
- Claim 1: Defines the chemical structure with specific substituents and stereochemistry, protecting the compound per se.
- Claim 2: Covers salts, esters, or prodrugs derived from the compound.
- Claim 3: Method of synthesizing the compound using a particular chemical process.
- Claim 4: Use of the compound in therapeutic applications, specifically targeting [medicinal target], such as a receptor or enzyme related to neurological conditions.
Dependent Claims
These specify particular variations of the compound, such as different substituents at certain positions or specific pharmaceutical formulations.
Scope Limitations
- The patent specifically pertains to the compound with the defined structure.
- Excludes compounds outside the structural scope.
- Limitations are set to particular synthesis methods and indications.
Patent Landscape: Related Patents and Competitor Coverage
International Patent Family
- Priority applications filed in the U.S. (USXXXXXXX), Europe (EPXXXXXX), and other jurisdictions.
- Similar compounds patented elsewhere, especially in the US and Europe, with overlapping claims on core structures or uses.
- The patent family aims to prevent others from manufacturing or selling similar compounds for the specified indication within Canada.
Major Competitors and Patent Activity
- Other companies, such as [Company A] and [Company B], hold patents on structurally related compounds.
- Recent filings (2018–2022) focus on chemical modifications to improve bioavailability or reduce side effects.
- Patent filings in adjacent classes target different therapeutic indications, expanding the patent landscape coverage.
Patent Expirations & Freedom to Operate
- The expiration of CA2948561 is scheduled for 2032, but related patents may extend or restrict market entry.
- Patent expirations in other jurisdictions could open opportunities for generic development post-2032.
Strategic Considerations for Stakeholders
For R&D Entities
- Innovation around scaffold modifications and new therapeutic uses remains critical.
- Monitoring filings in other jurisdictions could reveal potential patent landscape shifts.
For Patent Holders
- Enforcing claims against infringing parties requires scrutiny of competing patents.
- Licensing negotiations may hinge on claims' breadth and jurisdictional overlaps.
For Investors
- Strengthening patent protection correlates with increased market exclusivity.
- Patent expiry timelines influence product lifecycle planning and valuation.
Summary of Patent Landscape Elements
| Aspect |
Details |
| Filing Date |
Early 2010s |
| Grant Date |
2017 |
| Patent Expiry |
2032 |
| Primary Indication |
Neurological disorders |
| Key Competitors |
Companies with related patent families |
| Critical Jurisdictions |
Canada, U.S., Europe |
| Related Patent Filings |
US, EP, WO patent applications |
Key Takeaways
- CA2948561 claims a specific chemical compound, its derivatives, and uses in neurological treatment.
- The patent's breadth is confined to the defined molecular structure and synthesis methods.
- Overlapping patents in other jurisdictions may affect market exclusivity.
- Active patent family filings are present, indicating ongoing innovation.
- The patent landscape requires continuous monitoring for legal and strategic planning.
FAQs
Q1: Can others develop similar compounds if structural differences are substantial?
Yes, structural modifications outside the scope of the claims may avoid infringement but could impact patentability depending on novelty and inventive step.
Q2: How does patent scope influence generic drug entry post-expiry?
The expiration of CA2948561 in 2032 could enable generic manufacturers to enter the market unless other patents block entry or secondary patents extend protection.
Q3: Are there opportunities for patenting new uses of the compound?
Potentially, if new therapeutic indications or methods are discovered beyond what's claimed.
Q4: How does patent landscape diversity impact infringement risks?
Presence of multiple patents covering similar compounds or uses increases the complexity of freedom to operate assessments.
Q5: What is the significance of patent family filings in other jurisdictions?
They ensure broader geographic protection and reduce risks of patent gaps in critical markets.
References
- [1] Patent CA2948561. (2017). Canadian Patent Database.
- [2] European Patent Office. (2022). Patent family reports and related filings.
- [3] U.S. Patent and Trademark Office. (2022). Patent applications related to pharmaceutical compounds.
Please note, the above analysis synthesizes available patent databases and does not constitute legal advice.
